MLH1 and neoplasm: Deng et al. found that this specific BRAF mutation occurred in 87% of sporadic tumors with hypermethylated MLH1, whereas it was not present in any MSI tumor with a germline MLH1 mutation [55], hence, a ‘‘positive’’ BRAF mutation virtually excludes the possibility of Lynch syndrome.